Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia
Sponsor: Nanfang Li
Summary
Elevated aldosterone causes moderate to severe increase in blood pressure, and leads to various target organ damage including cardiovascular ones. Aldosterone has been considered one of the important risk factors for cardiovascular and cerebrovascular diseases. Currently, the use of mineralocorticoid receptor antagonists(MRA) has been proven to reduce blood pressure levels, but long-term prognostic data are lacking in hypertensive patients. Therefore, the purpose of this clinical trial is to assess the effect of MRA on cardiovascular disease in patients with Hypertension and Hyperaldosteronemia.
Official title: Effect of Mineralcorticoid Recept Antagonist on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia:A Multicenter Randomized Controlled Study
Key Details
Gender
All
Age Range
30 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
8000
Start Date
2023-04-16
Completion Date
2026-12-31
Last Updated
2023-04-18
Healthy Volunteers
No
Conditions
Interventions
Mineralocorticoid Receptor Antagonists(MRAs)
Participants will be treated with mineralocorticoid receptor antagonists(MRAs) in addition to the original antihypertensive drugs for 48 months.
Blank control
Participants will be treated with the original antihypertensive drugs for 48 months.
Locations (1)
Hypertension Center of People's Hospital of Xinjiang Uygur Autonomous Region
Ürümqi, Xinjiang, China